pulmonary fibrosis
Conditions
Interventions
Control group (44 cases):None
Group of pulmonary fibrosis :None
group of pulmonary fibrosis+Pefephen:Bifidobacteria Triple Viable Capsule, 210mg/capsule, two capsules per day, two capsules per time, taken by mouth for a total of 8 weeks
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Have a previous history of recurrent cough, expectoration, and/or hemoptysis; 2. All patients were diagnosed with pulmonary fibrosis by HRCT and respiratory doctors; 3.Currently in a stable condition, no antibiotics were used for nearly 2 months. 44 controls for lung tumors: 1. No history of chronic respiratory disease; 2.No history of antibiotic drug use; 3.No gastrointestinal and other system diseases
Exclusion criteria
Exclusion criteria: 1. Concomitant with history of Bronchial Asthma, Tuberculosis, Chronic Obstructive Lung Disease, Allergic Aspergillosis and Bronchiectasis; 2. Have a history of autoimmune disease; 3. Have symptoms of abdominal pain, diarrhea, or a history of clearly diagnosed gastrointestinal disease; 4. Have a history of acute and chronic heart, liver, kidney, and tumors; 5. Use of steroids within three months; 6 Coordination difficulties as well as contact difficulties.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute exacerbation rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in predominant bacteria in the subject's intestine and lungs;Changes of FVC and DLCO in lung function of subjects;T lymphoid immune cell number of subjects;Number of acute patient hospitalizations; | — |
Countries
China
Contacts
Public ContactHanhan Liu
Shanghai Sixth People's Hospital
Outcome results
None listed